| Literature DB >> 35774153 |
Teng Liu1, Shaofei Ni2, Wusheng Guo1.
Abstract
We report the first amine nucleophilic approach for the modular construction of enantioenriched protected α-quaternary amino acids. The key to success is the use of an alcohol solvent, which makes a rationally designed COOMe-bonded Cu-allenylidene electrophilic intermediate stable enough to couple with amine nucleophiles before its decomposition. The reaction features wide functional group tolerance with high enantioselectivity, typically >90% ee, and is amenable to the modification of commercially available bioactive molecules. The resultant protected α-amino acids could be readily converted into a number of precious enantioenriched amines featuring α-hindered tertiary carbon centers, which are otherwise synthetically quite challenging, including those of α-amino aldehyde, peptides or α-vinyl amino ester with >92% ee in excellent yields. This protocol could be utilized for the synthesis of the protected bioactive α-ethylnorvaline in 3 steps, a significant advancement in comparison to an 11-step sequence reported previously. This journal is © The Royal Society of Chemistry.Entities:
Year: 2022 PMID: 35774153 PMCID: PMC9200120 DOI: 10.1039/d2sc02318k
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.969
Scheme 1The asymmetric syntheses of (protected) α-quaternary amino acids: advances and challenges.
Fig. 1Cu-catalyzed elusive propargylation of aryl amines: (a) the reaction outcomes of the propargylation of aniline with S1 in different solvents on the basis of 19F NMR; (b) the asymmetric propargylation of amines towards the formation of protected α-quaternary amino acids.
Fig. 2The investigation of the reaction scope. Isolated yields were reported, and the ee value was evaluated by HPLC equipped with a chiral column. The reactions were performed on a 0.1 mmol scale at −30 °C for amino esters 3–19 and −40 °C for amino esters 21, 23–26, 28–31 and 33; other conditions are noted. Inset is the solid state of product 1 (CDCC-2092791) with only the hydrogen attached to the amino group shown for clarity. −40 °C. Using methanol as a solvent and reaction at 0 °C for 24 h. −30 °C. 0 °C for 24 h.
Fig. 3(a) The synthesis of the protected amino acid 1 at the gram-scale, and (b) synthetic applications of product 1: (i) LiOH (3.0 eq.), MeOH/H2O, rt, 24 h; (ii) DIBAL-H (2.5 eq.), toluene, −78 °C, 2 h; (iii) LiAlH4 (2.0 eq.), THF, 0 °C, 4 h; (iv) 6-iodoquinoline (1.1 eq.), Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), TEA (3.0 eq.) THF, rt, 24 h; (v) N-tosyl-2-iodoaniline (1.0 eq.), Pd(PPh3)2Cl2 (5 mol%), CuI (5 mol%), TMG (3.0 eq.), DMF, 40 °C, 24 h; (vi) Pd/C (10 mol%), H2, EtOH, rt, 4 h; (vii) Lindlar catalyst (2 mol%), H2, EtOH, rt, 30 min; (viii) from protected amino acid 2, CAN (3.0 eq.), MeCN/H2O, 0 °C, 2 h. Please see the ESI† for details.
Fig. 4(a and b) The derivatization of commercially available drug molecules; (c) the syntheses of enantioenriched peptides 49 and 50 from products 45 and 38, respectively; (d) a concise route for the synthesis of protected bioactive α-ethyl norvaline 52versus a multiple-step pathway reported previously. Please see the ESI† for details.